ホジキンリンパ腫の世界市場-2023年～2030年

市場概要

ホジキンリンパ腫の世界市場は、2022年に9億米ドルに達し、2030年には21億米ドルに達し、有利な成長が予測されています。世界のホジキンリンパ腫市場は、予測期間中（2023～2030年）にCAGR 9.8％を示すと予測されます。技術進歩の増加と新規製品への投資の増加が、ホジキンリンパ腫の市場動向の需要を押し上げています。

ホジキンリンパ腫の市場には、疾患の存在を立証する種類と治療法が含まれます。世界の若年成人の悪性腫瘍の15%はホジキンリンパ腫であり、全HLの95%を占める。新しい治療法の発売とリンパ腫患者の増加が、ホジキンリンパ腫の世界市場を推進する主な要因です。

ホジキンリンパ腫の市場範囲は、標的療法、化学療法、免疫療法、その他などの療法で構成され、ホジキンリンパ腫の市場シェアを拡大しています。ホジキンリンパ腫の世界市場は、研究開発の増加や各国における今後の新規製品承認などの要因により拡大しており、ホジキンリンパ腫市場の成長にも明るい見通しが生まれています。

市場力学

罹患率と死亡率の上昇がホジキンリンパ腫市場の成長を促進する

世界のホジキンリンパ腫市場の主要促進要因の1つは、ホジキンリンパ腫の有病率の増加です。cancer.netによると、2023年に米国で診断されるホジキンリンパ腫は8,830人（男性4,850人、女性3,980人）です。2000年代半ば以降、この病気の患者数は毎年1％ずつ減少しています。2020年には、世界中で83,087人のホジキンリンパ腫が診断されます。

2023年には米国で900人が死亡すると予測されている（男性540人、女性360人）。およそ1975年以降、医療の進歩により生存率は上昇しています。

ホジキンリンパ腫は小児から成人まで罹患する可能性があります。米国では、2つの年齢層で最も多くみられます。最初のグループは若年成人、特に20歳代です。もう一つは55歳以上です。通常の診断年齢は39歳です。この疾患は5歳以下の幼児ではまれであるが、15歳または19歳前後の10代で発見される最も一般的な悪性腫瘍です。

研究開発と新製品上市の増加がメーカーに有利な機会をもたらす

ホジキンリンパ腫患者に対するより良い治療法を求めて、研究者により様々な調査研究が行われています。現在、免疫チェックポイント阻害薬は、従来のBVと化学療法の組み合わせに加えて、BV（ブレンツキシマブ・ベドチン）との併用、化学療法との併用、単独治療として研究されています。

さらに、政府や他の様々な団体により、いくつかの進歩やイニシアチブが開始されています。例えば、リンパ腫専門研究プログラム（Lymphoma Specialized Programs of Research Excellence：Lymphoma SPOREs）の目標は、基礎研究の結果を迅速に治療現場に反映させることです。リンパ腫SPOREは、新しい免疫療法、最先端の標的治療、各患者の予後を把握するための革新的な技術の創出に資金を提供しています。

2022年11月10日、ADCETRIS（ブレンツキシマブ・ベドチン）は、ドキソルビシン、エトポシド、ビンクリスチン、プレドニゾン、シクロホスファミドと併用することで、高リスクの古典的ホジキンリンパ腫（cHL）の2歳以上の小児患者の治療薬として米国食品医薬品局（FDA）から承認されました。

高い治療費が市場の成長を妨げる

しかし、化学療法は高額であることや、治療による副作用が出始めることが市場の妨げになると予想されます。例えば、心血管系疾患やリンパ腫、急性白血病、固形がんを含む二次がんを含む悪影響が現れる可能性があります。

COVID-19影響分析

COVID-19の流行と世界の封鎖は、あらゆる業界の企業の財務状況に影響を及ぼしています。その結果、米国食品医薬品局（FDA）は、COVID-19健康緊急事態の期間中、スポンサーと研究者を支援し、試験参加者の安全を確保し、適正臨床実施（GCP）に従い、試験の完全性に対するリスクを低減するための一般的な考慮事項を含むガイドラインを発表しました。

ロシア・ウクライナ紛争影響分析

ロシア・ウクライナ紛争は、世界のホジキンリンパ腫市場に与える影響は低いと推定されます。しかし、原材料の輸出入の影響は、予測期間中、世界のホジキンリンパ腫市場の成長にほとんど影響を与えないと予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 技術の進歩と新製品上市の増加
    • 罹患率と死亡率の上昇
  • 抑制要因
    • 治療に伴う合併症
  • 機会
    • 研究開発と新製品の上市の増加
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 療法別

• 標的療法
• 化学療法
• 免疫療法
• その他

第8章 タイプ別

• 結節性硬化型ホジキンリンパ腫（NSCHL）
• 混合細胞性ホジキンリンパ腫（MCCHL）
• リンパ球豊富型ホジキンリンパ腫
• リンパ球減少型ホジキンリンパ腫
• その他

第9章 エンドユーザー別

• 病院
• 専門クリニック
• 外来手術センター
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • その他アジア太平洋地域
• 中東およびアフリカ
  • 主な地域別ダイナミクス

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• Merck & Co., Inc.
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Bristol Myers Squibb
• F. Hoffmann-La Roche Ltd
• Seagen Inc.
• Ono Pharmaceutical Co., Ltd.
• AstraZeneca
• Actinium Pharmaceuticals, Inc.
• Pfizer Inc.
• Affimed GmbH
• Incyte

第13章 付録

Market Overview

The Global Hodgkin's Lymphoma Market reached US$ 0.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 2.1 billion by 2030. The global Hodgkin's lymphoma market is expected to exhibit a CAGR of 9.8% during the forecast period (2023-2030). The increasing technological advancements and the growing investments in novel products are driving up demand for Hodgkin's lymphoma market trends.

The market for Hodgkin's lymphomas includes types and therapies that establish the existence of the disease. 15% of all malignancies in young adults worldwide are Hodgkin's lymphoma, which makes up 95% of all HLs. The launch of new treatments and an increase in patients with lymphomas are the main factors propelling the global market for Hodgkin's lymphoma.

The Hodgkin's lymphoma market scope comprises therapy as targeted therapy, chemotherapy, immunotherapy and others, which has increased the Hodgkin's lymphoma market share. The global market for Hodgkin's lymphoma is expanding as a result of factors including increasing research and development and their upcoming novel product approvals across countries are also creating a positive outlook for the Hodgkin's lymphoma market growth.

Market Dynamics

The Rising Incidence and Mortality Rates Will Drive the Growth of the Hodgkin's Lymphoma Market

One of the key drivers of the global Hodgkin's lymphoma market is the increasing prevalence of Hodgkin's lymphoma. According to cancer.net, there will be 8,830 Hodgkin lymphoma diagnoses in the US in 2023 (4,850 males and 3,980 females). Since the middle of the 2000s, there has been a 1% annual decline in the number of patients with this disease. In 2020, there will be 83,087 Hodgkin lymphoma diagnoses worldwide.

In 2023, it is predicted that this disease will cause 900 fatalities in the United States (540 deaths in males and 360 deaths in females). Since roughly 1975, the rate of survival has been increasing as a result of advancements in medical care.

Hodgkin lymphoma can affect both children and adults. In the US, two age categories are where it is most common. The first group consists of young adults, particularly those who are in their 20s. The second category includes those who are above 55. The usual diagnosis age is 39. Although the condition is rare in young children below the age of 5, it is the most prevalent malignancy detected in teenagers around the ages of 15 or 19.

Rising Research and Development and Novel Product Launches Creates Lucrative Opportunities for Manufacturers

Various research studies are being conducted by researchers for better treatment options for patients with Hodgkin's lymphoma as immune checkpoint inhibitors are currently being studied as a single treatment, when combined with BV (Brentuximab vedotin) and in conjunction with chemotherapy, in addition to traditional BV and chemotherapy combos.

Furthermore, several advancements and initiatives have been started by the government and various other organizations. For instance, The goal of the Lymphoma Specialized Programs of Research Excellence (Lymphoma SPOREs) is to swiftly translate results from fundamental research into therapeutic settings. The Lymphoma SPOREs fund the creation of fresh immunotherapies, cutting-edge targeted treatments and innovative techniques for figuring out each patient's prognosis.

On November 10, 2022, ADCETRIS (brentuximab vedotin), in conjunction with doxorubicin, etoposide, vincristine, prednisone and cyclophosphamide, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric patients who are two years or older with high-risk classical Hodgkin lymphoma (cHL).

High Cost Of Treatment Will Hamper the Growth of the Market.

However, it is anticipated that the market will be hampered by the expensive nature of chemotherapy and the beginning of side effects from the treatment. For instance, it's possible for negative consequences including cardiovascular disease and secondary cancers including lymphoma, acute leukemia and solid tumors to manifest.

COVID-19 Impact Analysis

The COVID-19 epidemic and the worldwide lockdown have had an effect on the financial health of businesses in all industries. As a result, the U.S. Food and Drug Administration (FDA) released guidelines for the duration of the COVID-19 health emergency that include general considerations to assist sponsors and researchers, ensure trial participants' safety, follow good clinical practice (GCP) and reduce risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global Hodgkin's lymphoma market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global Hodgkin's lymphoma market growth over the forecast period.

Segment Analysis

The global Hodgkin's lymphoma market is segmented based on therapy, type, end-user and region.

Nodular Sclerosis Hodgkin Lymphoma or NSCHL from Type Segment Accounts for 58.8% of Market Share Owing to High Incidence

Predominant nodular lymphocytes are a much more uncommon kind of lymphoma, this kind of Hodgkin's lymphoma includes lymphoma cells which are commonly referred to as "popcorn cells" due to their appearance. Dominant nodular lymphocytes when opposed to the more conventional form of the disease, Hodgkin's lymphoma is typically detected at its earliest stage and might need less intensive therapies.

The B-cells in lymph nodes in the neck or the chest region between the lungs are where nodular sclerosis typically begins. These B-cells develop into Reed-Sternberg cells, which are much larger, malignant cells. These cells aid in the diagnosis of Hodgkin lymphoma by medical professionals.

Sclerosis Nodular With 70% of cases being Hodgkin lymphoma or NSCHL, it is the most common kind of classical Hodgkin lymphoma (cHL). Lymph nodes that are affected have sclerosis-like fibrous structures. Similar rates of occurrence in men and women and very treatable. B symptoms are present in about 40% of cases.

Geographical Analysis

North America Accounted for Approximately 40.3% of the Market Share Owing to the Strong Presence of Major Players and the Advancements in Hodgkin's Lymphomas

Manufacturers have chances to expand their operations in this region because of the rising demand for Hodgkin's lymphoma for advancements in North America. The area has many producers and suppliers and its rapid economic development has raised industrial production of Hodgkin's lymphoma, which has increased the demand.

There are many manufacturers and suppliers in North America and as a result of the region's rapid economic growth, industrial production has expanded, feeding the desire for the research and development of novel products.

The market will grow as new technology for research and development emerge. Rising technological developments, governmental approvals and the introduction of new products all contribute to growth. People are becoming more aware of novel products and therapies, leading to the expansion of the market in this region. These factors are responsible for the dominance of North America.

Competitive Landscape

The major global players in the Hodgkin's lymphoma market include: Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Bristol Myers Squibb, Seagen Inc., Actinium Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., Pfizer Inc., AstraZeneca, Affimed GmbH and Incyte among others.

Why Purchase the Report?

• To visualize the global Hodgkin's lymphoma market segmentation based on therapy, type, end-user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Hodgkin's lymphoma market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global Hodgkin's lymphoma market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers / Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Therapy
• 3.2. Snippet by Type
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Technological Advancements and Novel Product Launches
    • 4.1.1.2. The Rising Incidence and Mortality Rates
  • 4.1.2. Restraints
    • 4.1.2.1. Complications Associated with the Treatments
  • 4.1.3. Opportunity
    • 4.1.3.1. Rising Research and Development and Novel Product Launches
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. By Therapy

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 7.1.2. Market Attractiveness Index, By Therapy
• 7.2. Targeted Therapy *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Chemotherapy
• 7.4. Immunotherapy
• 7.5. Others

8. By Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.1.2. Market Attractiveness Index, By Type
• 8.2. Nodular Sclerosis Hodgkin Lymphoma or NSCHL *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Mixed Cellularity Hodgkin Lymphoma or MCCHL
• 8.4. Lymphocyte-rich Hodgkin Lymphoma
• 8.5. Lymphocyte-depleted Hodgkin Lymphoma
• 8.6. Others

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Hospitals *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Specialty Clinics
• 9.4. Ambulatory Surgical Centers
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Spain
    • 10.3.6.5. Italy
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan

Australia

• 10.5.6.4. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Merck & Co., Inc. *
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Bristol Myers Squibb
• 12.3. F. Hoffmann-La Roche Ltd
• 12.4. Seagen Inc.
• 12.5. Ono Pharmaceutical Co., Ltd.
• 12.6. AstraZeneca
• 12.7. Actinium Pharmaceuticals, Inc.
• 12.8. Pfizer Inc.
• 12.9. Affimed GmbH
• 12.10. Incyte

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us